Therapix Biosciences (TRPX) - Tackling neurology with cannabinoids

12:17 EDT 29 Jun 2017 | Edison Investment Research

Edison Investment Research - Pharmaceutical & healthcare - Therapix Biosciences: Therapix is investigating the potential of new formulations of cannabinoids to address underserved diseases of the brain. It recently listed on NASDAQ in the US 2.3m ADS (worth $13.8m). The lead clinical program, THX-TS01, is currently in Phase II trials testing its potential for treating Tourette’s in adults and THX-ULD01 is scheduled to begin Phase I trials for the treatment of mild cognitive impairment (MCI) in mid-2017. Both programs should qualify for a 505(b)(2) pathway to streamline approval. We arrive at an initial valuation of $38.4m or $10.97 per ADS.
ISIN: US88339A2033

Original Article: Therapix Biosciences (TRPX) - Tackling neurology with cannabinoids


More From BioPortfolio on "Therapix Biosciences (TRPX) - Tackling neurology with cannabinoids"

Quick Search


Relevant Topics

Health care (or healthcare) is the diagnosis, treatment, and prevention of disease, illness, injury, and other physical and mental impairments in humans. Health care is delivered by practitioners in medicine, chiropractic, dentistry, nursing, pharmacy, a...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...